Tokyo - Delayed Quote • JPY
Kubota Pharmaceutical Holdings Co., Ltd. (4596.T)
At close: 3:15 PM GMT+9
Key Executives
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ryo Kubota M.D., Ph.D. | Founder, Chairman, CEO & President | 84.6M | -- | 1966 |
| Tomomi Sukagawa | Director of Investor Relations & Communication | -- | -- | -- |
| Iyo Ichikawa | Chief Business Officer & Director | -- | -- | 1991 |
Kubota Pharmaceutical Holdings Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Corporate Governance
Kubota Pharmaceutical Holdings Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
Recent Events Information Not Available
Upcoming Events
May 14, 2024
Kubota Pharmaceutical Holdings Co., Ltd. Earnings Call